About Biolife Solutions (NASDAQ:BLFS)
BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; contract aseptic manufacturing formulation, fill, and finish services of liquid media products; and precision thermal packaging products and cloud-hosted Web applications. It markets its products to the regenerative medicine, bio-banking, drug discovery markets, comprising hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, hair transplant centers, and suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLFS
CUSIPN/A
Phone425-402-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio6.58%
Quick Ratio5.36%
Price-To-Earnings
Trailing P/E Ratio-33.95
Forward P/E Ratio-79.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.02 million
Price / Sales9.16
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book9.90
Profitability
EPS (Most Recent Fiscal Year)($0.21)
Net Income$-2,510,000.00
Net Margins-22.82%
Return on Equity-37.37%
Return on Assets-26.41%
Miscellaneous
Employees40
Outstanding Shares14,150,000
Biolife Solutions (NASDAQ:BLFS) Frequently Asked Questions
What is Biolife Solutions' stock symbol?
Biolife Solutions trades on the NASDAQ under the ticker symbol "BLFS."
How were Biolife Solutions' earnings last quarter?
Biolife Solutions (NASDAQ:BLFS) issued its earnings results on Thursday, March, 8th. The medical equipment provider reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The medical equipment provider earned $3.13 million during the quarter, compared to analysts' expectations of $3.10 million. Biolife Solutions had a negative return on equity of 37.37% and a negative net margin of 22.82%. View Biolife Solutions' Earnings History.
When is Biolife Solutions' next earnings date?
What price target have analysts set for BLFS?
3 brokerages have issued twelve-month price objectives for Biolife Solutions' shares. Their predictions range from $5.00 to $9.00. On average, they expect Biolife Solutions' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Biolife Solutions.
Who are some of Biolife Solutions' key competitors?
Some companies that are related to Biolife Solutions include Rockwell Medical (RMTI), Vision Sciences (CGNT), Fonar (FONR), Helius Medical Technologies (HSDT), Zynex (ZYXI), Second Sight Medical (EYES), Viveve Medical (VIVE), Edap Tms (EDAP), IRIDEX (IRIX), BioSig Technologies (BSGM), Semler Scientific (SMLR), Stereotaxis (STXS), Soleno Therapeutics (SLNO), Digirad (DRAD) and Nexeon MedSystems (NXNN).
Who are Biolife Solutions' key executives?
Biolife Solutions' management team includes the folowing people:
- Mr. Michael P. Rice, Pres, CEO & Director (Age 55)
- Mr. Roderick de Greef, CFO, Principal Accounting officer & Sec. (Age 58)
- Dr. Aby J. Mathew Ph.D., Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 46)
- Ms. Karen Foster, VP of Operations (Age 58)
- Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance
Has Biolife Solutions been receiving favorable news coverage?
News stories about BLFS stock have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biolife Solutions earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 47.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Biolife Solutions' major shareholders?
Biolife Solutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include CASDIN CAPITAL, LLC (7.10%). Company insiders that own Biolife Solutions stock include Michael Rice and Thomas Girschweiler. View Institutional Ownership Trends for Biolife Solutions.
How do I buy shares of Biolife Solutions?
Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biolife Solutions' stock price today?
One share of BLFS stock can currently be purchased for approximately $7.13.
How big of a company is Biolife Solutions?
Biolife Solutions has a market capitalization of $100.01 million and generates $11.02 million in revenue each year. The medical equipment provider earns $-2,510,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Biolife Solutions employs 40 workers across the globe.
How can I contact Biolife Solutions?
Biolife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]
MarketBeat Community Rating for Biolife Solutions (BLFS)
MarketBeat's community ratings are surveys of what our community members think about Biolife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biolife Solutions (NASDAQ:BLFS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Biolife Solutions in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible downside of 1.82%. The high price target for BLFS is $9.00 and the low price target for BLFS is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $6.50 | $6.50 | $6.00 |
| Price Target Upside: | 1.82% downside | 23.81% upside | 11.11% upside | 0.33% upside |
Biolife Solutions (NASDAQ:BLFS) Consensus Price Target History
Biolife Solutions (NASDAQ:BLFS) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Biolife Solutions (NASDAQ:BLFS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biolife Solutions (NASDAQ BLFS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 38.50%
Institutional Ownership Percentage: 12.09%
Biolife Solutions (NASDAQ BLFS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | Michael Rice | CEO | Sell | 12,540 | $7.18 | $90,037.20 | 146,157 |  |
| 4/9/2018 | Thomas Girschweiler | Director | Sell | 1,025,000 | $5.26 | $5,391,500.00 | | |
| 3/15/2018 | Michael Rice | CEO | Sell | 12,540 | $5.27 | $66,085.80 | | |
| 2/15/2018 | Michael Rice | CEO | Sell | 12,540 | $5.26 | $65,960.40 | 152,057 | |
| 1/16/2018 | Michael Rice | CEO | Sell | 12,540 | $5.57 | $69,847.80 | 152,057 | |
| 8/8/2014 | Raymond W Cohen | Chairman | Buy | 1,250 | $2.48 | $3,100.00 | | |
| 5/20/2014 | Raymond W Cohen | Chairman | Buy | 4,000 | $2.39 | $9,560.00 | | |
| 5/14/2014 | Aby J Mathew | CTO | Buy | 8,600 | $2.33 | $20,038.00 | | |
| 5/14/2014 | Michael Rice | CEO | Buy | 8,000 | $2.56 | $20,480.00 | | |
| 5/13/2014 | Michael Rice | CEO | Buy | 12,767 | $2.26 | $28,853.42 | | |
(Data available from 1/1/2013 forward)
Biolife Solutions (NASDAQ BLFS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Biolife Solutions (BLFS) Expected to Announce Quarterly Sales of $3.81 Million
www.americanbankingnews.com - April 25 at 4:56 AM |
| -$0.03 EPS Expected for Biolife Solutions (BLFS) This Quarter
www.americanbankingnews.com - April 23 at 3:18 AM |
| Biolife Solutions (BLFS) Given $8.83 Consensus Target Price by Brokerages
www.americanbankingnews.com - April 20 at 9:22 PM |
| Michael Rice Sells 12,540 Shares of Biolife Solutions (BLFS) Stock
www.americanbankingnews.com - April 18 at 7:46 PM |
| Insider Selling: Biolife Solutions (BLFS) Director Sells 1,025,000 Shares of Stock
www.americanbankingnews.com - April 10 at 10:17 PM |
 | Casdin Capital to Become Shareholder in BioLife Solutions
finance.yahoo.com - April 9 at 9:27 AM |
| $3.81 Million in Sales Expected for Biolife Solutions (BLFS) This Quarter
www.americanbankingnews.com - April 8 at 5:02 AM |
| Biolife Solutions (BLFS) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 6:58 PM |
| Zacks: Analysts Set $8.50 Price Target for Biolife Solutions (BLFS)
www.americanbankingnews.com - April 3 at 9:19 AM |
 | BioLife Solutions (BLFS) Announces Prelim. Q1 Revenue of $3.8 Million
www.streetinsider.com - April 2 at 4:41 PM |
| Maxim Group Analysts Give Biolife Solutions (BLFS) a $9.00 Price Target
www.americanbankingnews.com - April 2 at 3:16 PM |
 | BioLife solutions announces preliminary Q1 results; shares ahead 7% premarket
seekingalpha.com - April 2 at 9:43 AM |
| BioLife Solutions Announces Preliminary First Quarter 2018 Revenue of $3.8 Million, up 61% Year-over-Year and 22% Sequentially
finance.yahoo.com - April 2 at 9:43 AM |
| BioLife Solutions and SAVSU Technologies to be Awarded Second Patent for Next Generation Cold Chain Technologies Designed for Cell and Gene Therapies
finance.yahoo.com - March 26 at 9:37 AM |
| Biolife Solutions (BLFS) Expected to Post Quarterly Sales of $3.14 Million
www.americanbankingnews.com - March 22 at 8:08 AM |
| Biolife Solutions (BLFS) Expected to Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - March 20 at 5:14 AM |
| Maxim Group Analysts Give Biolife Solutions (BLFS) a $8.00 Price Target
www.americanbankingnews.com - March 19 at 5:02 PM |
| BioLife Solutions Inc (BLFS) CEO Sells $66,085.80 in Stock
www.americanbankingnews.com - March 16 at 8:32 PM |
| BioLife Solutions CryoStor® Cell Freeze Media Highlighted in Mayo Clinic/MD Anderson Journal Article on Preservation of Patient-Derived Xenografts for Cancer Research
finance.yahoo.com - March 13 at 9:31 AM |
| BioLife Solutions (BLFS) Coverage Initiated at Northland Securities
www.americanbankingnews.com - March 12 at 1:44 PM |
| Maxim Group Reiterates $8.00 Price Target for BioLife Solutions (BLFS)
www.americanbankingnews.com - March 10 at 5:10 PM |
| Brokerages Expect BioLife Solutions Inc (BLFS) to Announce ($0.03) Earnings Per Share
www.americanbankingnews.com - March 10 at 3:22 PM |
| BioLife Solutions (BLFS) Announces Earnings Results
www.americanbankingnews.com - March 9 at 10:35 AM |
| BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 5:36 PM |
| BioLife Solutions, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 5:36 PM |
| When Will BioLife Solutions Inc (NASDAQ:BLFS) Breakeven?
finance.yahoo.com - March 8 at 5:36 PM |
| BioLife Solutions to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update on March 8, 2018
finance.yahoo.com - March 1 at 5:00 PM |
| Michael Rice Sells 12,540 Shares of BioLife Solutions Inc (BLFS) Stock
www.americanbankingnews.com - February 16 at 10:20 PM |
| BioLife Solutions Executes OEM Agreement with MilliporeSigma
finance.yahoo.com - February 13 at 9:24 AM |
| BioLife Solutions Announces SAVSU Alliance with World Courier
finance.yahoo.com - January 23 at 3:56 PM |
| SAVSU Technologies and BioLife Solutions Increase evo® Intellectual Property Estate with Notice of Allowance of New Patent for Cold Chain Technologies
finance.yahoo.com - January 18 at 10:51 AM |
| Insider Selling: BioLife Solutions Inc (BLFS) CEO Sells 12,540 Shares of Stock
www.americanbankingnews.com - January 17 at 7:34 PM |
| BioLife Solutions to Attend and Present at Upcoming Investor & Scientific Conferences
finance.yahoo.com - January 16 at 9:56 AM |
| Is There An Opportunity With BioLife Solutions Inc’s (NASDAQ:BLFS) 21.60% Undervaluation?
finance.yahoo.com - January 4 at 4:58 PM |
| BioLife Solutions, Inc. :BLFS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:37 PM |
| Shire (SHPG) vs. BioLife Solutions (BLFS) Head to Head Review
www.americanbankingnews.com - December 23 at 9:20 PM |
| Analyzing BioLife Solutions (BLFS) & Adamis Pharmaceuticals (ADMP)
www.americanbankingnews.com - December 15 at 3:30 PM |
| Should BioLife Solutions Inc’s (undefined:BLFS) Earnings Decline In Recent Times Worry You?
finance.yahoo.com - December 13 at 10:16 AM |
| The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
finance.yahoo.com - December 1 at 5:15 PM |
| BioLife Solutions' (BLFS) Buy Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - November 30 at 12:42 PM |
| BioLife Solutions Executes Additional Long-Term Supply Agreement with Leading T Cell Therapy Customer
finance.yahoo.com - November 29 at 10:03 AM |
| Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences
finance.yahoo.com - November 28 at 8:02 AM |
| Head to Head Review: XenoPort (XNPT) and BioLife Solutions (BLFS)
www.americanbankingnews.com - November 24 at 9:10 PM |
| Brokerages Expect BioLife Solutions, Inc. (BLFS) to Post ($0.07) Earnings Per Share
www.americanbankingnews.com - November 14 at 9:46 AM |
| Edited Transcript of BLFS earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 14 at 12:49 AM |
| Short Interest in BioLife Solutions, Inc. (BLFS) Expands By 44.7%
www.americanbankingnews.com - November 13 at 2:32 AM |
| BioLife Solutions, Inc. (BLFS) Price Target Raised to $8.00
www.americanbankingnews.com - November 12 at 12:29 PM |
| BioLife Solutions, Inc. (BLFS) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM |
| BioLife Solutions Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:48 PM |
| ETFs with exposure to BioLife Solutions, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 5:40 PM |
Biolife Solutions (NASDAQ:BLFS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biolife Solutions (NASDAQ:BLFS) Income Statement, Balance Sheet and Cash Flow Statement
Biolife Solutions (NASDAQ BLFS) Stock Chart for Thursday, April, 26, 2018
Loading chart…
